Sökning: onr:"swepub:oai:DiVA.org:uu-494889" >
Immuno-Modulatory E...
Immuno-Modulatory Effects of Dexamethasone in Severe COVID-19 : A Swedish Cohort Study
-
- Asif, Sana, M.D, PhD student (författare)
- Uppsala universitet,Anestesiologi och intensivvård
-
- Frithiof, Robert (författare)
- Uppsala universitet,Anestesiologi och intensivvård
-
- Larsson, Anders (författare)
- Uppsala universitet,Klinisk kemi
-
visa fler...
-
- Franzén, Stephanie (författare)
- Uppsala universitet,Anestesiologi och intensivvård
-
- Bülow Anderberg, Sara (författare)
- Uppsala universitet,Anestesiologi och intensivvård
-
- Kristensen, Bjarne (författare)
- Thermo Fisher Scientific, DK-84 3450 Alleröd, Denmark.
-
- Hultström, Michael, 1978- (författare)
- Uppsala universitet,Anestesiologi och intensivvård,Integrativ Fysiologi
-
- Lipcsey, Miklós (författare)
- Uppsala universitet,Hedenstiernalaboratoriet
-
visa färre...
-
(creator_code:org_t)
- 2023-01-09
- 2023
- Engelska.
-
Ingår i: Biomedicines. - : MDPI. - 2227-9059. ; 11:1
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Dexamethasone (Dex) has been shown to decrease mortality in severe coronavirus disease 2019 (COVID-19), but the mechanism is not fully elucidated. We aimed to investigate the physiological and immunological effects associated with Dex administration in patients admitted to intensive care with severe COVID-19. A total of 216 adult COVID-19 patients were included-102 (47%) received Dex, 6 mg/day for 10 days, and 114 (53%) did not. Standard laboratory parameters, plasma expression of cytokines, endothelial markers, immunoglobulin (Ig) IgA, IgM, and IgG against SARS-CoV-2 were analyzed post-admission to intensive care. Patients treated with Dex had higher blood glucose but lower blood lactate, plasma cortisol, IgA, IgM, IgG, D-dimer, cytokines, syndecan-1, and E-selectin and received less organ support than those who did not receive Dex (Without-Dex). There was an association between Dex treatment and IL-17A, macrophage inflammatory protein 1 alpha, syndecan-1 as well as E-selectin in predicting 30-day mortality. Among a subgroup of patients who received Dex early, within 14 days of COVID-19 debut, the adjusted mortality risk was 0.4 (95% CI 0.2-0.8), i.e., 40% compared with Without-Dex. Dex administration in a cohort of critically ill COVID-19 patients resulted in altered immunological and physiologic responses, some of which were associated with mortality.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Anestesi och intensivvård (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Anesthesiology and Intensive Care (hsv//eng)
Nyckelord
- COVID-19
- cytokines
- dexamethasone
- hypoxia
- intensive care
- treatment timing
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Asif, Sana, M.D, ...
-
Frithiof, Robert
-
Larsson, Anders
-
Franzén, Stephan ...
-
Bülow Anderberg, ...
-
Kristensen, Bjar ...
-
visa fler...
-
Hultström, Micha ...
-
Lipcsey, Miklós
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Anestesi och int ...
- Artiklar i publikationen
-
Biomedicines
- Av lärosätet
-
Uppsala universitet